IM Cannabis Corp (TSE:IMCC) has released an update.
IM Cannabis Corp. reported a substantial 50% revenue growth in Q3 2024 for its German subsidiary, Adjupharm GmbH, following the partial legalization of cannabis in Germany earlier that year. The company attributes this success to its strategic initiatives and a robust supply chain that meets the rising demand for cannabis products. IM Cannabis Corp. is an international player focused on providing premium cannabis to the medical markets in Israel and Germany, building on a data-driven approach and a global supply chain.
For further insights into TSE:IMCC stock, check out TipRanks’ Stock Analysis page.
